445303-96-8

Basic information

• Product Name: Benzenamine, 3-(difluoromethyl)-4-fluoro- (9CI)
• Synonyms: Benzenamine, 3-(difluoromethyl)-4-fluoro- (9CI);3-(DIFLUOROMETHYL)-4-FLUOROANILINE
• CAS NO: 445303-96-8
• Molecular Formula: C7H6F3N
• Molecular Weight: 161.1244496
• Product Categories: HALIDE
• Mol File: 445303-96-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: Benzenamine, 3-(difluoromethyl)-4-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 3-(difluoromethyl)-4-fluoro- (9CI)(445303-96-8)
• EPA Substance Registry System: Benzenamine, 3-(difluoromethyl)-4-fluoro- (9CI)(445303-96-8)

Safety Data

• Hazardous Substances Data: 445303-96-8(Hazardous Substances Data)

Upstream product

• 27996-87-8 2-fluoro-5-nitrobenzaldehye 
• 63878-71-7 2‐(difluoromethyl)‐1‐fluoro‐4‐nitrobenzene 

Downstream Products

• 1448529-64-3 2-(difluoromethyl)-1-fluoro-4-isothiocyanato-benzene 
• 1574312-05-2 C₁₇H₁₇F₃N₄O₂S 
• 1574312-11-0 1-[3-(difluoromethyl)-4-fluoro-phenyl]-3-[[5-(isopropylsulfamoyl)-2-pyridyl]methyl]thiourea 
• 1572514-70-5 C₁₈H₁₇F₃N₂O₄S 
• 1572516-61-0 5-chloro-3-[[3-(difluoromethyl)-4-fluorophenyl]carbamoyl]-2-fluorobenzene-1-sulfonyl chloride 
• 1572511-11-5 C₁₉H₁₉F₃N₂O₄S 
• 1572514-12-5 C₁₈H₁₆F₄N₂O₄S 
• 1572514-11-4 C₁₈H₁₅ClF₄N₂O₄S 
• 1572510-72-5 C₁₇H₁₇F₃N₂O₃S 

Relevant articles and documents

A kind of IDO inhibitor and use thereof

The embodiment of the invention provides general formula (I) compound or its pharmaceutically acceptable salts, stereoisomers, a tautomeric form each other, polymorphs, solvate, prodrug, metabolite or isotope derivatives, wherein the substituents R1

TRIAZOLES AS NR2B RECEPTOR INHIBITORS

Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B

TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.